Status of work in February
AOTMiT begins work on the Ministry of Health’s orders in March:
- Qalsody (tofersen) in the treatment of amyotrophic lateral sclerosis
- Bellix (bilastinum) in the symptomatic treatment of allergic rhinoconjunctivitis (seasonal and perennial) and urticaria
- Truqap (capivasertib) in the treatment of breast cancer patients
- Arexvy respiratory syncytial virus (RSV) vaccine
- Trimbow (beclometasone, formoterol, glycopyrronium bromide) for treating asthma
- Trimbow (beclometasone, formoterol, glycopyrronium bromide) for the treatment of COPD
- Fabhalta (iptacopan) in the treatment of patients with paroxysmal nocturnal hemoglobinuria
The listed orders are available on the AOTMiT Public Information Bulletin.